Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more
Solvonis Therapeutics plc (SVNS) - Total Liabilities
Latest total liabilities as of June 2025: GBX2.61 Million GBX
Based on the latest financial reports, Solvonis Therapeutics plc (SVNS) has total liabilities worth GBX2.61 Million GBX as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Solvonis Therapeutics plc - Total Liabilities Trend (2018–2024)
This chart illustrates how Solvonis Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Solvonis Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Solvonis Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crown Place VCT PLC
LSE:CRWN
|
UK | GBX1.17 Million |
|
PYX Resources Limited
LSE:PYX
|
UK | GBX7.24 Million |
|
SigmaBroadband Co
PINK:SGRB
|
USA | $2.58 Million |
|
Seneca Growth Capital VCT PLC
LSE:HYG
|
UK | GBX219.00K |
Liability Composition Analysis (2018–2024)
This chart breaks down Solvonis Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solvonis Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solvonis Therapeutics plc (2018–2024)
The table below shows the annual total liabilities of Solvonis Therapeutics plc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX119.00K | -70.83% |
| 2023-12-31 | GBX408.00K | +5.97% |
| 2022-12-31 | GBX385.00K | -83.39% |
| 2021-12-31 | GBX2.32 Million | +89.53% |
| 2021-05-31 | GBX1.22 Million | +37.42% |
| 2020-05-31 | GBX890.00K | +71.15% |
| 2019-05-31 | GBX520.00K | +242.11% |
| 2018-05-31 | GBX152.00K | -- |